BA
GYRE icon

BlackRock Advisors’s Gyre Therapeutics GYRE Stock Holding History

BlackRock Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5
Closed -$1K – 3726
2016
Q2 		$1K Hold
5
– – ﹤0.01% 3737
2016
Q1 		$1K Hold
5
– – ﹤0.01% 3743
2015
Q4 		$2K Hold
5
– – ﹤0.01% 3773
2015
Q3 		$3K Buy
+5
New +$7.63K ﹤0.01% 3728
2014
Q3 		– Sell
-12
Closed -$41K – 3697
2014
Q2 		$41K Sell
12
-17
-59% -$55.5K ﹤0.01% 3289
2014
Q1 		$110K Sell
29
-20
-41% -$74K ﹤0.01% 2989
2013
Q4 		$160K Buy
49
+24
+96% +$94.6K ﹤0.01% 2789
2013
Q3 		$104K Buy
25
+3
+14% +$12.1K ﹤0.01% 2939
2013
Q2 		$73K Buy
+22
New +$83.7K ﹤0.01% 3055

Other funds holding GYRE

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock Advisors's GYRE Position: Q3 2016 in Review

BlackRock Advisors sold out of Gyre Therapeutics (GYRE) in Q3 2016, closing a stake of 5 shares — an estimated $1K sold.

BlackRock Advisors first reported a position in GYRE in Q2 2013 and held it in 9 quarters. The position peaked at $160K in Q4 2013. 29 funds tracked by Wall St. Rank hold GYRE as of Q3 2016.

  • BlackRock Advisors reported no remaining Gyre Therapeutics position as of Q3 2016 after selling out during the quarter.
  • BlackRock Advisors sold 5 Gyre Therapeutics shares in Q3 2016, an estimated $1K.
  • BlackRock Advisors first reported a position in Gyre Therapeutics in Q2 2013 and held it in 9 quarters.
  • BlackRock Advisors's Gyre Therapeutics position peaked at $160K in Q4 2013.
  • 29 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2016.

Based on BlackRock Advisors's 13F filing for Q3 2016, filed 8 Nov 2016.